FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085323547> ?p ?o ?g. }

• W2085323547 endingPage "1714" @default.
• W2085323547 startingPage "1709" @default.
• W2085323547 abstract "Metastatic colorectal cancer is generally incurable. The most active regimen available, 5-fluorouracil (5-FU) and folinic acid (Leucovorin), produces response rates of approximately 25% to 30%. Methyl-lomustine is a nitrosourea with modest activity against colorectal cancer. A randomized trial was undertaken to evaluate the impact the addition of methyl-lomustine would have on response, duration of survival, and survival rates in patients with advanced colorectal cancer.The methyl-lomustine/5-FU/Leucovorin (MFL) regimen consisted of methyl-lomustine (110 mg/m2), administered on Day 1 of each 8-week cycle with six weekly boluses of 5-FU (600 mg/m2), and Leucovorin (500 mg/m2). The FL treatment arm consisted of the administration of 5-FU and Leucovorin as described above. Patients were evaluated for response and toxicity after each 8-week cycle.Of 319 patients included in this trial, 297 (93.1%) had disease evaluable for response and toxicity: 145 received MFL, and 152 received FL. In this trial, 526 courses of MFL and 529 courses of FL were administered. Methyl-lomustine/5-FU/Leucovorin treatment resulted in 4 complete and 30 partial responses (response rate, 21.9%), and FL treatment resulted in 9 complete and 33 partial responses (response rate, 26.4%). There was no significant difference in median survival duration between patients in the two arms (MFL = 48 weeks, FL = 51 weeks). However, MFL was significantly more toxic with greater myelosuppression than was FL (Grade 3-4 neutropenia: MFL = 56 patients, FL = 27 patients, P < 0.001; Grade 3-4 thrombocytopenia: MFL = 49 patients, FL = 2 patients, P < 0.001; Grade 3-4 anemia: MFL = 15 patients, FL = 6 patients, P < 0.001; and more prolonged median duration of granulocytopenia: MFL = 9 days, FL = 7 days, P < 0.001; and thrombocytopenia: MFL = 14 days, FL = 7.5 days, P < 0.001).Because the addition of methyl-lomustine in the MFL schedule markedly increased the toxicity of the regimen and because the FL regimen was as effective as MFL, the authors recommend that Leucovorin and 5-FU remain the treatment choice for treating patients with metastatic colorectal cancer." @default.
• W2085323547 created "2016-06-24" @default.
• W2085323547 creator A5018278944 @default.
• W2085323547 creator A5019894304 @default.
• W2085323547 creator A5030323121 @default.
• W2085323547 creator A5031997645 @default.
• W2085323547 creator A5038348446 @default.
• W2085323547 creator A5045601889 @default.
• W2085323547 creator A5047818279 @default.
• W2085323547 creator A5054037529 @default.
• W2085323547 creator A5075037144 @default.
• W2085323547 creator A5087376683 @default.
• W2085323547 date "1995-11-15" @default.
• W2085323547 modified "2023-09-26" @default.
• W2085323547 title "Randomized phase III Study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer" @default.
• W2085323547 cites W1988208601 @default.
• W2085323547 cites W1996974717 @default.
• W2085323547 cites W2019727694 @default.
• W2085323547 cites W2024260681 @default.
• W2085323547 cites W2042276405 @default.
• W2085323547 cites W2047510518 @default.
• W2085323547 cites W2052357987 @default.
• W2085323547 cites W2053935259 @default.
• W2085323547 cites W2053995869 @default.
• W2085323547 cites W2079458411 @default.
• W2085323547 cites W2148700329 @default.
• W2085323547 cites W2321004095 @default.
• W2085323547 cites W2396200506 @default.
• W2085323547 cites W2896665591 @default.
• W2085323547 cites W4253234031 @default.
• W2085323547 doi "https://doi.org/10.1002/1097-0142(19951115)76:10<1709::aid-cncr2820761006>3.0.co;2-5" @default.
• W2085323547 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8625038" @default.
• W2085323547 hasPublicationYear "1995" @default.
• W2085323547 type Work @default.
• W2085323547 sameAs 2085323547 @default.
• W2085323547 citedByCount "12" @default.
• W2085323547 countsByYear W20853235472012 @default.
• W2085323547 countsByYear W20853235472013 @default.
• W2085323547 countsByYear W20853235472014 @default.
• W2085323547 countsByYear W20853235472016 @default.
• W2085323547 countsByYear W20853235472018 @default.
• W2085323547 crossrefType "journal-article" @default.
• W2085323547 hasAuthorship W2085323547A5018278944 @default.
• W2085323547 hasAuthorship W2085323547A5019894304 @default.
• W2085323547 hasAuthorship W2085323547A5030323121 @default.
• W2085323547 hasAuthorship W2085323547A5031997645 @default.
• W2085323547 hasAuthorship W2085323547A5038348446 @default.
• W2085323547 hasAuthorship W2085323547A5045601889 @default.
• W2085323547 hasAuthorship W2085323547A5047818279 @default.
• W2085323547 hasAuthorship W2085323547A5054037529 @default.
• W2085323547 hasAuthorship W2085323547A5075037144 @default.
• W2085323547 hasAuthorship W2085323547A5087376683 @default.
• W2085323547 hasConcept C121608353 @default.
• W2085323547 hasConcept C126322002 @default.
• W2085323547 hasConcept C141071460 @default.
• W2085323547 hasConcept C2776694085 @default.
• W2085323547 hasConcept C2776755627 @default.
• W2085323547 hasConcept C2777063308 @default.
• W2085323547 hasConcept C2779429289 @default.
• W2085323547 hasConcept C2779434656 @default.
• W2085323547 hasConcept C2779804826 @default.
• W2085323547 hasConcept C2780456651 @default.
• W2085323547 hasConcept C2781413609 @default.
• W2085323547 hasConcept C29730261 @default.
• W2085323547 hasConcept C526805850 @default.
• W2085323547 hasConcept C71924100 @default.
• W2085323547 hasConcept C90924648 @default.
• W2085323547 hasConceptScore W2085323547C121608353 @default.
• W2085323547 hasConceptScore W2085323547C126322002 @default.
• W2085323547 hasConceptScore W2085323547C141071460 @default.
• W2085323547 hasConceptScore W2085323547C2776694085 @default.
• W2085323547 hasConceptScore W2085323547C2776755627 @default.
• W2085323547 hasConceptScore W2085323547C2777063308 @default.
• W2085323547 hasConceptScore W2085323547C2779429289 @default.
• W2085323547 hasConceptScore W2085323547C2779434656 @default.
• W2085323547 hasConceptScore W2085323547C2779804826 @default.
• W2085323547 hasConceptScore W2085323547C2780456651 @default.
• W2085323547 hasConceptScore W2085323547C2781413609 @default.
• W2085323547 hasConceptScore W2085323547C29730261 @default.
• W2085323547 hasConceptScore W2085323547C526805850 @default.
• W2085323547 hasConceptScore W2085323547C71924100 @default.
• W2085323547 hasConceptScore W2085323547C90924648 @default.
• W2085323547 hasIssue "10" @default.
• W2085323547 hasLocation W20853235471 @default.
• W2085323547 hasLocation W20853235472 @default.
• W2085323547 hasOpenAccess W2085323547 @default.
• W2085323547 hasPrimaryLocation W20853235471 @default.
• W2085323547 hasRelatedWork W2012864969 @default.
• W2085323547 hasRelatedWork W2026758790 @default.
• W2085323547 hasRelatedWork W2092470860 @default.
• W2085323547 hasRelatedWork W2101429368 @default.
• W2085323547 hasRelatedWork W2127026223 @default.
• W2085323547 hasRelatedWork W2383619798 @default.
• W2085323547 hasRelatedWork W2410470690 @default.
• W2085323547 hasRelatedWork W2417931553 @default.
• W2085323547 hasRelatedWork W2509837252 @default.
• W2085323547 hasRelatedWork W3201435628 @default.
• W2085323547 hasVolume "76" @default.

• next